Novel immunotherapy for several types of tumors such as lung cancer including NSCLC

摘要

The present invention relates to peptides, nucleic acids, and cells for use in immunotherapy. In particular, the present invention relates to cancer immunotherapy. The present invention relates to a tumor-associated cytotoxic T cell (CTL) peptide epitope that acts as an active pharmaceutical ingredient of a vaccine composition that stimulates an anti-tumor immune response, alone or in combination with other tumor-related peptides. Further on. The present invention provides more than 70 novel peptide sequences derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions to elicit anti-tumor immune responses, and variants thereof About.